关于SGLT2抑制剂对IgA脏病和膜性脏病的药理标:一个门德尔的随机化研究
Xin Lv1,2, Yan Shang1,2, Yong Ning1,2
1Department of Nephrology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.
Frontiers in pharmacology
|June 7, 2024
概括
-葡萄糖共运输体2 (SGLT2) 抑制剂在治疗IgA病 (IgAN) 方面表现有前途. 这项研究发现,达帕格利弗洛辛可能通过LCN2和AGER基因向IGAN,这表明潜在的治疗途径.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
- 遗传学 遗传学是一种遗传学.
背景情况:
- 新兴的研究突出显示,-葡萄糖共运输体2 (SGLT2) 抑制剂是初级淋巴细胞疾病的潜在治疗方法.
- IgA脏病 (IgAN) 和膜性脏病 (MN) 是主要的淋巴细胞疾病,其中SGLT2抑制剂的有效性正在研究中.
研究的目的:
- 调查潜在的药理标,将SGLT2抑制剂与IgA脏病 (IgAN) 和膜性脏病 (MN) 联系起来.
- 探索SGLT2抑制剂在这些病中可能发挥治疗作用的分子机制.
主要方法:
- 在全基因组关联研究 (GWAS) 数据集上使用单变量门德尔随机化 (MR) 分析.
- 采用联合定位,比较毒基因组学数据库 (CTD) 和表型扫描分析来识别基因-疾病和药物-基因关联.
- 用基因和基因组的京都百科全书 (KEGG) 分析了免疫信号通路,以确定目标基因.
主要成果:
- 确定了8个与Igan和14个与MN因果相关的药物标.
- 发现 LCN2 和 AGER 基因与达帕格利弗洛辛和 IgAN 共局部; LCN2 是一个危险因素,AGER 是保护性的.
- LCN2与IL-17通路有关,AGER与中性粒细胞外细胞陷 (NETs) 信号;对于其他SGLT2抑制剂,没有发现与Igan或MN的显著联系.
结论:
- 提供了特定SGLT2抑制剂和IGAN之间的因果关系的证据.
- 达帕格利弗洛辛可能通过LCN2和AGER基因对IGAN产生影响,突出显示潜在的治疗点.
相关概念视频
Glucose Transporters
22.7K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.7K
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Glucose Absorption Into the Small Intestine
31.6K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.6K
Secondary Active Transport
7.0K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
7.0K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
173
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
173


